Bullion and oil appear in the lineup of power players that Doug Casey thinks investors can count on as the world slips deeper and deeper into what he calls the “Greater Depression.” Despite the raging economic storm and Doug’s doubts that Western civilization’s governments will take the actions needed to quell it, though, the Chairman of Casey Research is nowhere close to calling the game. In fact, he sees silver lining in the clouds of crisis—opportunity—and expresses optimism that technological advances, coupled with capital rebuilding once over-consumption runs its course, will prevail eventually. The Energy Report caught up with the peripatetic author, publisher and professional international investor between polo matches in New Zealand, one of several nation-states he calls home from time to time.

The Energy Report: You’ve been discussing what you’re calling “crisis and opportunity,” and in fact have a summit by that same name coming up in Las …

Bullion and oil appear in the lineup of power players that Doug Casey thinks investors can count on as the world slips deeper and deeper into what he calls the “Greater Depression.” Despite the raging economic storm and Doug’s doubts that Western civilization’s governments will take the actions needed to quell it, though, the Chairman of Casey Research is nowhere close to calling the game. In fact, he sees silver lining in the clouds of crisis—opportunity—and expresses optimism that technological advances, coupled with capital rebuilding once over-consumption runs its course, will prevail eventually. The Gold Report caught up with the peripatetic author, publisher and professional international investor between polo matches in New Zealand, one of several nation-states he calls home from time to time.

The Gold Report: You’ve been discussing what you’re calling “crisis and opportunity,” and in fact have a summit by that same name coming up in Las …

Leo Pharma is establishing a Chinese affiliate to market Leo Pharma's portfolio of drugs for the treatment of the chronic skin disease psoriasis and other dermatological products. Leo Pharma's leading psoriasis brand, Daivobet, has just been approved by the Chinese authorities and can now be marketed in China, according to the company. Leo Pharma's new company in [...]

The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber with any questions as the agency will investigate each of the claims further before taking action or issuing more definitive statements on the reported concerns. Some highlights from this table of products that are sold by public-traded pharma and biotech companies are listed below in the following format: active ingredient (brand name) - company(ies) - new safety information reported. Duloxetine (Cymbalta) - Eli Lilly (LLY) - Urinary retention Heparin - Baxter (BAX) & APP Pharma (APPX) - Anaphylactic-type reactions Lapatinib (Tykerb) - GlaxoSmithKline (GSK) – Liver toxicity Lenalidomide (Revlimid) - Celgene (CELG) – ...